Application Serial No.: 09/936,985

Group Art Unit: 1645

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the

application:

**Listing of Claims:** 

1. (Currently amended): An immunogenic composition comprising at least one

Streptococcus pneumoniae polysaccharide-protein conjugate, formulated with at least one

unconjugated Streptococcus pneumoniae protein antigen, and an adjuvant which is a

preferential inducer of a TH1 response.

2. (Currenlty amended): The immunogenic composition of claim 1, wherein the

<u>unconjugated Streptococcus pneumoniae</u> protein antigen is an outer surface protein or a

secreted protein of Streptococcus pneumoniae.

3. (Currently amended): The immunogenic composition of claim 1, wherein the

unconjugated Streptococcus pneumoniae protein antigen is a toxin, adhesion or lipoprotein of

Streptococcus pneumoniae.

4. (Currently amended): The immunogenic composition of claim 1, wherein the

<u>unconjugated Streptococcus pneumoniae</u> protein antigen is selected from the group <u>consisting</u>

of: pneumolysin, PspA or transmembrane deletion variants thereof, PspC or transmembrane

deletion variants thereof, PsaA or transmembrane deletion variants thereof, glyceraldehyde-3-

phosphate dehydrogenase, and CbpA or transmembrane deletion variants thereof.

5. (Cancelled).

6. (Currently amended): The immunogenic composition of claim 1, wherein the

protein <u>carrier in the polysaccharide-protein</u> conjugate is selected from the group consisting

of: Diphtheria toxoid, Tetanus toxoid, CRM197, Keyhole Limpet Haemocyanin (KLH),

protein derivative of Tuberculin (PPD), and protein D from H. influenzae.

2

Application Serial No.: 09/936,985

'Group Art Unit: 1645

7. (Previously presented): An immunogenic composition of claim 1 which comprises at least four pneumococcal polysaccharide antigens from different serotypes.

- 8. (Previously presented): An immunogenic composition as claimed in claim 1, wherein the adjuvant comprises at least one of the following: 3D-MPL, a saponin immunostimulant, or an immunostimulatory CpG oligonucleotide.
- 9. (Currently amended): An immunogenic composition as claimed in claim 8, wherein the adjuvant comprises a carrier selected from the group <u>consisting of emprising</u>: an oil in water emulsion, liposomes, and an aluminium salt.
  - 10. (Cancelled).
- 11. (Currently amended): A vaccine comprising the immunogenic composition of claim 1 any one of claims 1-9.
- 12. (Withdrawn): A method of preventing or ameliorating *Streptococcus* pneumoniae infection in a patient over 55 years of age, comprising administering an effective amount of a vaccine comprising a *Streptococcus pneumoniae* polysaccharide, at least one *Streptococcus pneumoniae* protein, and a TH1 inducing adjuvant.
  - 13. (Cancelled).
- 14. (Withdrawn): A method of making the immunogenic composition of claim 1, comprising the steps of:

selecting one or more pneumococcal polysaccharide antigen(s); selecting one or more pneumococcal protein antigen(s); selecting a TH1 inducing adjuvant; and mixing said polysaccharide and protein antigens and adjuvant with a suitable excipient.

Application Serial No.: 09/936,985

'Group Art Unit: 1645

15. (Withdrawn): A method of preventing or ameliorating Otitis media in Infants, comprising administering a safe and effective amount of a vaccine comprising a *Streptococcus pneumoniae* polysaccharide antigen, a *Streptococcus pneumoniae* protein antigen and a TH1 inducing adjuvant, to said Infant.